Ratings & Metrics
Financial Documents
| Entity | Document Type | Tax ID |
|---|---|---|
| American Brain Tumor Association | IRS Form 990 | 23-7286648 |
| American Brain Tumor Association | Audited Financial Statements | 23-7286648 |
|
Entity: American Brain Tumor Association Document Type: IRS Form 990 Tax ID: 23-7286648 |
|
Entity: American Brain Tumor Association Document Type: Audited Financial Statements Tax ID: 23-7286648 |
Governance & Transparency
Top Salaries
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Ralph Devitto | President/CEO | $245,460 |
| 2 | Kelly Sitkin | Chief Development Officer | $172,756 |
| 3 | Nicole Willmarth | Chief Mission Officer | $151,962 |
|
1 Name: Ralph Devitto Title: President/CEO Compensation: $245,460 |
|
2 Name: Kelly Sitkin Title: Chief Development Officer Compensation: $172,756 |
|
3 Name: Nicole Willmarth Title: Chief Mission Officer Compensation: $151,962 |
Analysts' Notes
In an email correspondence with CharityWatch dated 9/2/2020, the Senior Director, Finance and Audit for the American Brain Tumor Association (ABTA) confirmed that the ABTA 2019 IRS Form 990 tax filing, signed and dated 8/6/2020 by ABTA's President & CEO, contains an error in Part IX, the Statement of Functional Expenses. More specifically, the reported "Management and general expenses" in Part IX, column (C) and the reported "Fundraising expenses" in Part IX, column (D) have been transposed. In other words, column (C), with a reported total of $900,356, consists of ABTA's reported Fundraising expenses, and column (D), with a reported total of $794,388, consists of ABTA's reported Management & General expenses. ABTA's Senior Director, Finance and Audit confirmed that the ABTA audited Statement of Functional Expenses for the year ended December 31, 2019 reports the correct Fundraising and Management & General expenses. |
According to the American Brain Tumor Association (ABTA) audit of December 31, 2019 (Note B10, Donated Items and Services), ABTA received in-kind donated items and services in 2019 on which it placed a total value of $62,117. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
According to the American Brain Tumor Association (ABTA) audit of December 31, 2019 (Note O, Subsequent Events): "The direct and indirect impacts of the current COVID-19 outbreak on ABTA's donors, vendors, operations, and financing agreements are currently unknown, as is the duration and severity of any impacts that the ABTA may experience. Management is currently unable to quantify the effects that this situation will have on its operations and financial position; however they may be significant. "The United States and global markets experienced significant declines in value resulting from uncertainty caused by the world-wide coronavirus pandemic. The ABTA is closely monitoring the investment portfolio and its liquidity and are actively working to minimize the impact of these declines. These [audited] financial statements do not include adjustments to fair value that have resulted from these declines. "On May 1, 2020, the ABTA obtained a $439,000 loan through the United States Small Business Administration's Paycheck Protection Program. The loan matures in May 2022, is uncollateralized, and bears interest at 1.0%; however, payment of principal and interest are deferred until the ABTA submits its application for loan forgiveness, as the loan may be eligible for forgiveness if certain conditions regarding the use of the loan proceeds are met." |